Login Register Cart 0
Generic placeholder image

Current Drug Therapy

Editor-in-Chief

ISSN (Print): 1574-8855
ISSN (Online): 2212-3903

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Quality by Design Enabled Formulation Optimization of Rabeprazole Sodium Mucoadhesive Microcapsules for the Treatment of Gastroesophageal Reflux Disease

Author(s): Jayanti Panda, Suryakanta Swain* and Muddana Eswara Bhanoji Rao

Volume 19, Issue 2, 2024

Published on: 30 May, 2023

Page: [250 - 261] Pages: 12

DOI: 10.2174/1574885518666230516102626

Price: $65

Abstract

Aims: The present research describes the implementation of quality by-design principles for developing the mucoadhesive microcapsules of rabeprazole sodium for treating gastroesophageal reflux disease conditions.

Background: In addition, a holistic QbD-based product development strategy was implemented, where the target product profile was defined based on desired product quality of mucoadhesive microcapsules. Based on TPP, the critical quality attributes were identified. The identification of CMAs was carried out with the help of risk assessment and factor screening exercises, which indicated drugpolymer ratio (X1), temperature (X2), and stirring speed (X3) as the influential factors.

Methods: The mucoadhesive microcapsules of rabeprazole sodium were prepared by a solvent evaporation method, and 33 Box-Behnken optimization design was used for the optimization of the selected factors, and mucoadhesive microcapsules formulations were evaluated for particle size (μm), drug entrapment efficiency (%), mucoadhesion (%), and in vitro drug release (Q18h) in percentage characteristics. Mathematical data analysis was performed to fit the two-factor interaction model, and optimized mucoadhesive microcapsules formulation was selected.

Results: The optimized mucoadhesive microcapsules indicated desired formulation characteristics with smaller particle size, good entrapment efficiency, better mucoadhesion, and sustained drug release characteristics.

Conclusion: In a nutshell, the studies vouch for the successful development of mucoadhesive microcapsules for oral delivery of rabeprazole sodium which could be used to manage gastroesophageal reflux disease condition.

« Previous Next »
Graphical Abstract

[1]
Maret-Ouda J, Markar SR, Lagergren J. Gastroesophageal reflux disease. JAMA 2020; 324(24): 2565.
[http://dx.doi.org/10.1001/jama.2020.21573] [PMID: 33351044]
[2]
Patti MG. An evidence-based approach to the treatment of gastroesophageal reflux disease. JAMA Surg 2016; 151(1): 73-8.
[http://dx.doi.org/10.1001/jamasurg.2015.4233] [PMID: 26629969]
[3]
Yadlapati R, DeLay K. Proton pump inhibitory-refractory gastroesophageal reflux disease. Med Clin North Am 2019; 103(1): 15-27.
[http://dx.doi.org/10.1016/j.mcna.2018.08.002] [PMID: 30466671]
[4]
Chen J, Brady P. Gastroesophageal reflux disease: Pathophysiology, diagnosis, and treatment. Gastroenterol Nurs 2019; 42(1): 20-8.
[http://dx.doi.org/10.1097/SGA.0000000000000359] [PMID: 30688703]
[5]
Kahrilas PJ, Miner P, Johanson J, Mao L, Jokubaitis L, Sloan S. Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease. Dig Dis Sci 2005; 50: 2009-18.
[http://dx.doi.org/10.1007/s10620-005-3000-3]
[6]
Das S, Kaur S, Rai VK. Gastro-retentive drug delivery systems: a recent update on clinical pertinence and drug delivery. Drug Deliv Transl Res 2021; 11(5): 1849-77.
[http://dx.doi.org/10.1007/s13346-020-00875-5] [PMID: 33403646]
[7]
Lim PWY, Goh KL. Review Article: Efficacy and safety of rabeprazole in treating gastroesophageal reflux disease. J Gastroenterol Hepatol 2004; 19(s3) (Suppl. 3): S61-8.
[http://dx.doi.org/10.1111/j.1440-1746.2004.03592.x] [PMID: 15324384]
[8]
Awasthi R, Kulkarni GT, Pawar VK, Garg G. Optimization studies on gastroretentive floating system using response surface methodology. AAPS PharmSciTech 2012; 13(1): 85-93.
[http://dx.doi.org/10.1208/s12249-011-9730-y] [PMID: 22135108]
[9]
Pawar VK, Kansal S, Garg G, Awasthi R, Singodia D, Kulkarni GT. Gastroretentive dosage forms: A review with special emphasis on floating drug delivery systems. Drug Deliv 2011; 18(2): 97-110.
[http://dx.doi.org/10.3109/10717544.2010.520354] [PMID: 20958237]
[10]
Sato Y, Kawashima Y, Takeuchi H, Yamamoto H. In vitro and in vivo evaluation of riboflavin-containing microballoons for a floating controlled drug delivery system in healthy humans. Int J Pharm 2004; 275(1-2): 97-107.
[http://dx.doi.org/10.1016/j.ijpharm.2004.01.036] [PMID: 15081141]
[11]
Patel H, Desai N, Patel P, et al. Pharmacokinetic evaluation of differential drug release formulations of rabeprazole in dogs. Drug Dev Ind Pharm 2019; 45(9): 1459-67.
[http://dx.doi.org/10.1080/03639045.2019.1628249] [PMID: 31216902]
[12]
Swain S, Behera UA, Beg S, et al. Design and characterization of enteric-coated controlled release mucoadhesive microcapsules of Rabeprazole sodium. Drug Dev Ind Pharm 2013; 39(4): 548-60.
[http://dx.doi.org/10.3109/03639045.2012.676047] [PMID: 22512732]
[13]
Tan Y, Si X, Zhong L, et al. Development and validation of dissolution testings in acidic media for rabeprazole sodium delayed-release capsules. Drug Dev Ind Pharm 2016; 42(10): 1669-77.
[http://dx.doi.org/10.3109/03639045.2016.1161644] [PMID: 27066697]
[14]
Rahman M, Panda SS, Beg S. Pharmaceutical QbD: Omnipresence in the product development lifecycle. EPR 2017; p. 1.
[15]
Beg S, Hasnain MS, Rahman M, Swain S. Chapter 1 - Introduction to Quality by Design (QbD): Fundamentals, Principles, and Applications. In: Pharmaceutical Quality by Design. Academic Press 2019.
[16]
Ali J, Pramod K, Tahir MA, Charoo NA, Ansari SH. Pharmaceutical product development: A quality by design approach. Int J Pharm Investig 2016; 6(3): 129-38.
[http://dx.doi.org/10.4103/2230-973X.187350] [PMID: 27606256]
[17]
Swain S, Parhi R, Jena BR, Babu SM. Quality by design: Concept to applications. Curr Drug Discov Technol 2019; 16(3): 240-50.
[http://dx.doi.org/10.2174/1570163815666180308142016] [PMID: 29521238]
[18]
Beg SA, Robaian M, Rahman M, Sarim IS, Alruwaili N, Kumar PS. Pharmaceutical drug product development and process optimization: Effective use of quality by design. (1st ed.), New York: Apple Academic Press 2020.
[http://dx.doi.org/10.1201/9780367821678]
[19]
Applications and practical case studies. Beg S. Design of experiments for pharmaceutical product developmentsingapore: Springer-Nature 2021; II. a
[http://dx.doi.org/10.1007/978-981-33-4351-1]
[20]
Applications and practical case studies. Beg S. Design of experiments for pharmaceutical product developmentsingapore: Springer-Nature 2021; I. b
[http://dx.doi.org/10.1007/978-981-33-4351-1]
[21]
Applications and practical case studies. Beg S. Design of experiments for pharmaceutical product developmentsingapore: Springer-Nature 2021; II. a
[http://dx.doi.org/10.1007/978-981-33-4351-1]
[22]
Applications and practical case studies. Beg S. Design of experiments for pharmaceutical product developmentsingapore: Springer-Nature 2021; I. b
[http://dx.doi.org/10.1007/978-981-33-4351-1]
[23]
Bansal S, Beg S, Asthana A, et al. QbD-enabled systematic development of gastroretentive multiple-unit microballoons of itopride hydrochloride. Drug Deliv 2016; 23(2): 437-51.
[http://dx.doi.org/10.3109/10717544.2014.916771] [PMID: 24865292]
[24]
Gupta KR, Joshi RR, Chawla RB, Wadodkar SG. UV spectrophotometric method for the estimation of itopride hydrochloride in pharmaceutical formulation. eJ Chem 2010; 7(S1): 49-54.
[25]
Swain S, Behera A, Dinda SC, et al. Formulation design, optimization and pharmacodynamic evaluation of sustained release mucoadhesive microcapsules of venlafaxine HCl. Indian J Pharm Sci 2014; 76(4): 354-63.
[PMID: 25284934]
[26]
Swain S, Meher D, Patra C, Sruti J, Dinda S, Rao ME. Design and characterization of sustained release mucoadhesive microspheres of tolterodine tartrate. Curr Drug Deliv 2013; 10(4): 413-26.
[http://dx.doi.org/10.2174/1567201811310040006] [PMID: 23215776]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy